Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Application

This pharmaceutical secondary standard can also be used as follows:Development of three spectrophotometric methods to determine meloxicam in its pharmaceutical formulationsVoltammetric determination of meloxicam in pharmaceutical formulations using a boron-doped diamond electrode (BDDE)High-performance liquid chromatography-based quantitative analysis of meloxicam in its different tablet formulationsDevelopment and validation of a reversed-phase HPLC method for the separation and estimation of meloxicam in its pharmaceutical dosage formsQuantification of meloxicam and piroxicam from plasma samples using a liquid chromatography method combined with UV detection

Footnote

To see an example of a Certificate of Analysis for this material enter LRAB7807 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.

General description

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Meloxicam is an oxicam derivative and belongs to the group of non-steroidal anti-inflammatory drugs (NSAID), used for its analgesic, anti-inflammatory, and antipyretic properties. It acts by inhibiting the activity of prostaglandin synthetase, thereby preventing the synthesis of prostaglandins and decreasing inflammation.